Mannkind Corp (MNKD)
$1.35 0.05 (3.57%)
17:10 EST MNKD Stock Quote Delayed 15 Minutes
Previous Close $1.35
Market Cap 196.20M
PE Ratio -1.12
Volume (Avg. Vol.) 2.19M
Day's Range 1.33 - 1.42
52-Week Range 0.94 - 2.34
Dividend & Yield N/A (N/A)
MNKD Stock Predictions, Articles, and Mannkind Corp News
- From InvestorPlace
- From the Web
Things are not looking good for MannKind Corporation (MNKD), even following the relaunch of its inhaled insulin Afrezza.
Stark pessimism for MNKD stock is to be expected, but underappreciated factors could bring an unlikely surprise for MannKind.
Don't hold on to MannKind (MNKD) stock unless you want to experience a repeat of the SunEdison (SUNE) selloff. (You don't).
3 Stocks to Watch on Tuesday: MannKind Corporation (MNKD), Valeant Pharmaceuticals Intl Inc (VRX) and Solazyme Inc (SZYM)
MannKind (MNKD) and Valeant Pharmaceuticals (VRX) look set to open Tuesday down big after releasing financial results, but Solazyme (SZYM) could run hot.
With a new plan for Afrezza on deck, coupled with nearly half its float sold short, traders could squeeze some profit out of MNKD stock yet.
3 Stocks to Watch on Tuesday: Shake Shack Inc (SHAK), MannKind Corporation (MNKD) and Urban Outfitters, Inc. (URBN)
Shake Shack (SHAK) is slumping amid a not-so-rosy 2016 estimate, MannKind (MNKD) is surging ahead of earnings and Urban Outfitters (URBN) is reveling in an earnings beat.
MannKind (MNKD) stock has been on a painful downward slide for a year now. Don't hold out hope for change.
MannKind (MNKD) stock is likely in its last days as a public company. Here's why the inhaled-insulin-maker should pray for an acquisition.
Samsung warning raises Apple (AAPL) iPhone worries, MannKind (MNKD) is dumped by Sanofi and Walt Disney (DIS) downgraded on ESPN fears.
Sanofi (SNY) terminated its licensing agreement to commercialize Afrezza, ruining MannKind (MNKD) stock, and perhaps sealing the fate of the company.
KaloBios (KBIO) CEO Martin Shkreli is good evidence that people who have contempt for laws -- and decency -- will eventually defy both.
Why MannKind Corporation (MNKD), Electronic Arts Inc. (EA) and GameStop Corp. (GME) Are 3 of Today’s Worst Stocks
MannKind (MNKD), Electronic Arts (EA) and GameStop (GME) couldn't win for losing on Monday.
Friday’s Vital Data: MannKind Corporation (MNKD), Exxon Mobil Corporation (XOM), and Cisco Systems, Inc. (CSCO)
MannKind (MNKD) jumps on Tel Aviv listing, Exxon Mobil (XOM) gets a price target lift and Cisco (CSCO) issues light guidance.
The psychology of the market remains out of whack as a December rate hike nears. Meanwhile, investors take shelter behind the volatility.
Mannkind (MNKD) stock is booming today as the company announced that it plans to sell up to 50 million shares to Israeli ETFs.
Wednesday’s Vital Data: SunEdison Inc (SUNE), MannKind Corporation (MNKD) and Tesla Motors Inc (TSLA)
SunEdison (SUNE) gets pounded on debt, MannKind (MNKD) calls jump on rebound hopes, and Tesla (TSLA) puts pile on Morgan Stanley comments.
The MannKind (MNKD) stock price is falling off a cliff Tuesday as investors fret about liquidity issues and poor Afrezza sales.
Why MannKind Corporation (MNKD), Endurance International Group Hldgs Inc (EIGI) and Visa Inc. (V) Are 3 of Today’s Worst Stocks
MannKind (MNKD), Endurance International (EIGI) and Visa (V) were Monday's biggest losers, but for understandable reasons. Here's what happened.
From Simply Wall St
Michael Castagna became the CEO of MannKind Corporation (NASDAQ:MNKD) in 2017. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth that the<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/is-mannkind-corporations-nasdaqmnkd-ceo-overpaid-relative-to-its-peers/">Read More...</a></div>
From Analyst Ratings
H.C. Wainwright analyst Oren Livnat maintained a Buy rating on MannKind (MNKD – Research Report) today and set a price target of $2.50. The company’s shares closed last Monday at $1.32. According to TipRanks.com, Livnat is a 5-star analyst with an average return of 12.7% and a 55.8% success rate. Livnat covers the Healthcare sector,
From Seeking Alpha
The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader